Physician profile
Giuseppe Condemi
NPI 1083660781
$5,681.19
in general payments reported to CMS, 2019-2025
60 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $271 · 2020: $658 · 2021: $1,788 · 2022: $1,740 · 2023: $731 · 2024: $494.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,224.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $515.78 | 2019-2023 | |
| Janssen Biotech, INC. | $434.03 | 2020-2023 | |
| Amgen INC. | $375.48 | 2019-2024 | Krystexxa, Lumakras |
| Daiichi Sankyo INC. | $324.92 | 2020-2023 | Injectafer |
| E.R. Squibb & Sons, L.L.C. | $306.57 | 2020-2023 | Opdivo |
| Astrazeneca Pharmaceuticals LP | $271.51 | 2020-2023 | Imfinzi |
| Seagen INC. | $266.82 | 2021-2023 | Tukysa, Padcev |
| Astellas Pharma US INC | $234.85 | 2020-2023 | Xtandi, Padcev |
| Blueprint Medicines Corporation | $234.31 | 2020-2024 | Ayvakit |
| Incyte Corporation | $199.59 | 2019-2023 | Jakafi |
| Abbvie INC. | $174.84 | 2021-2023 | Venclexta |
| Exelixis INC. | $172.32 | 2021-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $134.81 | 2021-2022 | |
| Foundation Medicine, INC. | $131.09 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $130.71 | 2020-2023 | Keytruda |
Show all 59 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Giuseppe Condemi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.